The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
November 28, 2022
View Complete Issue         Table of Contents 2019 
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
November 28, 2022 (Issue: 1664)
The FDA has approved margetuximab-cmkb (Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
Article code: 1664g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.